NASDAQ:NXTC - NextCure Stock Price, News & Analysis

+0.31 (+1.05 %)
(As of 08/22/2019 04:00 PM ET)
Today's Range
Now: $29.83
50-Day Range
MA: $20.73
52-Week Range
Now: $29.83
Volume39,585 shs
Average Volume76,922 shs
Market Capitalization$677.59 million
P/E RatioN/A
Dividend YieldN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NXTC



Sales & Book Value

Annual SalesN/A
Book Value$7.86 per share



Market Cap$677.59 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.15. The business earned $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

3 equities research analysts have issued 1 year target prices for NextCure's stock. Their predictions range from $25.00 to $33.00. On average, they anticipate NextCure's share price to reach $28.00 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

Headlines about NXTC stock have been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NextCure earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for NextCure.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SPX Flow (FLOW), Alphabet (GOOG), Guardant Health (GH), Exelixis (EXEL), CME Group (CME), Biogen (BIIB), Activision Blizzard (ATVI), ANSYS (ANSS), Amgen (AMGN) and Adobe (ADBE).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

When does NextCure's lock-up period expire?

NextCure's lock-up period expires on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its public offering on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of NextCure's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are NextCure's major shareholders?

NextCure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (11.93%), Sofinnova Investments Inc. (11.50%), Citadel Advisors LLC (4.99%), Cormorant Asset Management LP (4.56%), Hillhouse Capital Management LTD. (4.46%) and Matthews International Capital Management LLC (2.05%). Company insiders that own NextCure stock include Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which institutional investors are buying NextCure stock?

NXTC stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sofinnova Investments Inc., Citadel Advisors LLC, Cormorant Asset Management LP, Hillhouse Capital Management LTD., Matthews International Capital Management LLC, Fosun International Ltd and BlackRock Inc.. Company insiders that have bought NextCure stock in the last two years include Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $29.83.

How big of a company is NextCure?

NextCure has a market capitalization of $677.59 million. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  15
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by Staff

Featured Article: Options Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel